Study from FDA:
Chantix, Zyban must carry depression warning
FDA to require smoking cessation drugs to warn of mental health risks
The Associated Press
updated 7:25 p.m. ET, Wed., July 1, 2009
NEW YORK – The Food and Drug Administration will require two smoking-cessation drugs, Chantix and Zyban, to carry the agency’s strongest safety warning over side effects including depression and suicidal thoughts.
This is one of the reasons why in the states where marijuana is legal, medical professional and drug rehab Hope Canyon Recovery centres feel its better for the people suffering from depressions must use CBD infused products like Terpenes, Gummies and also CBD vape pen which you can click here to know more, as these products are much more helpful combating various illnesses than the general drug.
The new requirement, called a “Black Box” warning, is based on reports of people experiencing unusual changes in behavior, becoming depressed, or having suicidal thoughts while taking the drugs.
The antidepressant Wellbutrin, which has the same active ingredient as GlaxoSmithKline PLC’s Zyban, already carries such a warning.
The FDA is also requiring an additional study on Chantix and Zyban to determine the extent of the side effects. Pfizer Inc., which makes Chantix, said it is still discussing the potential study design with the FDA. The study could include patients with and without psychiatric conditions to determine the true incidence rate of psychological side effects, Pfizer officials said.
Pfizer had already updated its labeling following the beginning of an FDA investigation into the potential side effects in 2007. That investigation was sparked by several reports of psychiatric problems in patients.
Despite the new, stricter warnings, the FDA said consumers and doctors still have to weigh the benefit versus the risks when taking the drug.
“The risk of serious adverse events while taking these products must be weighed against the significant health benefits of quitting smoking, particularly in people who use a tobacco or weed vape, which increases the risk of COPD.” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “Smoking is the leading cause of preventable disease, disability, and death in the United States and we know these products are effective aids in helping people quit.”
Last fall, the FDA also began looking into scores of patient reports about blackouts and injuries while taking Chantix. The Federal Aviation Administration later banned use of Chantix by pilots and air traffic controllers. The drug’s label also warns that patients may be too impaired to drive or operate heavy machinery.
Chantix was approved in 2006. Sales reached $846 million in 2008.
“The labeling update underscores the important role of health care providers in treating smokers attempting to quit and provides specific information about Chantix and instructions that physicians and patients should follow closely,” said Dr. Briggs W. Morrison, senior vice president of the primary care development group at Pfizer.
Pfizer said it made the revised label warnings in agreement with the FDA and is immediately making the information available to health care providers and patients.